Accelerated in-vitro release testing methods for extended-release parenteral dosage forms

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 7, 2012, Pages 986-996

  Shen, Jie ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

accelerated in vitro release testing; extended release parenteral dosage forms; quality control; USP apparatus

Indexed keywords

DRUG; MICROSPHERE;

DISCRIMINANT ANALYSIS; DRUG DOSAGE FORM; DRUG ELUTING STENT; DRUG RELEASE; DRUG SOLUBILITY; IMPLANTABLE PORT SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; PARENTERAL DRUG ADMINISTRATION; PH; QUALITY CONTROL; REVIEW; TEMPERATURE; UNITED STATES;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; INFUSIONS, PARENTERAL; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL;

EID: 84862200324     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01482.x     Document Type: Review

References (91)

1. Davis JM, et al,. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 5: 741-773. (Pubitemid 24151095)
2. Simone EA, et al,. Polymeric carriers: role of geometry in drug delivery. Expert Opin Drug Deliv 2008; 12: 1283-1300.
3. Wu F, Jin T,. Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech 2008; 4: 1218-1229.
4. Huynh NT, et al,. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 2009; 2: 201-209.
5. Bhardwaj U, et al,. PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. Int J Pharm 2010; 1-2: 78-86.
6. Huang Y, et al,. In vitro and in vivo performance of a dual drug-eluting stent (DDES). Biomaterials 2010; 15: 4382-4391.
7. Martinez MN, et al,. Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products. J Control Release 2010; 1: 2-7.
8. Larsen C, et al,. Role of in vitro release models in formulation development and quality control of parenteral depots. Expert Opin Drug Deliv 2009; 12: 1283-1295.
9. Noyes AA, Whitney WR,. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-934.
10. Dokoumetzidis A, Macheras P,. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 2006; 1-2: 1-11. (Pubitemid 44247428)
11. Siewert M, et al,. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 2003; 1: E7.
12. D'Souza SS, DeLuca PP,. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech 2005; 2: E323-E328.
13. Dong CM, et al,. In vitro degradation and controlled release behavior of D,L-PLGA50 and PCL-b-D,L-PLGA50 copolymer microspheres. J Control Release 2005; 1: 53-64.
14. D'Souza SS, DeLuca PP,. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res 2006; 3: 460-474.
15. Iyer SS, et al,. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant. Int J Pharm 2007; 1-2: 119-125. (Pubitemid 47043367)
16. Neubert A, et al,. Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. J Control Release 2008; 1: 2-8.
17. Aso Y, et al,. Effect of temperature on mechanisms of drug release and matrix degradation of poly(d,l-lactide) microspheres. J Control Release 1994; 1: 33-39.
18. Shameem M, et al,. A short-term (accelerated release) approach to evaluate peptide release from PLGA depot formulations. AAPS J 1999; 3: 1-6.
19. Burgess DJ, et al,. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS J 2004; 1: 100-111.
20. Burgess DJ, et al,. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci 2002; 2: E7.
21. Martinez M, et al,. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society annual meeting. J Control Release 2008; 2: 79-87.
22. Zolnik BS, et al,. Elevated temperature accelerated release testing of PLGA microspheres. J Control Release 2006; 3: 293-300. (Pubitemid 43737147)
23. Burgess DJ, et al,. Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP. Pharm Res 2002; 11: 1761-1768. (Pubitemid 35305531)
24. Shi Y, Li L,. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2005; 6: 1039-1058. (Pubitemid 41701203)
25. Patil GV,. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res 2003; 3: 219-247. (Pubitemid 36555058)
26. Jain JP, et al,. Role of polyanhydrides as localized drug carriers. J Control Release 2005; 3: 541-563. (Pubitemid 40476140)
27. Zalfen AM, et al,. Controlled release of drugs from multi-component biomaterials. Acta Biomater 2008; 6: 1788-1796.
28. Faisant N, et al,. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci 2002; 4: 355-366. (Pubitemid 34436923)
29. Arifin DY, et al,. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems. Adv Drug Deliv Rev 2006; 12-13: 1274-1325.
30. Alexis F,. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int 2005; 1: 36-46. (Pubitemid 40032749)
31. Kumar R, Palmieri MJ, Jr,. Points to consider when establishing drug product specifications for parenteral microspheres. AAPS J 2010; 1: 27-32.
32. Koizumi T, Panomsuk SP,. Release of medicaments from spherical matrices containing drug in suspension: theoretical aspects. Int J Pharm 1995; 1: 45-49.
33. von Burkersroda F, et al,. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 21: 4221-4231.
34. Zolnik BS, Burgess DJ,. Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 2007; 3: 338-344. (Pubitemid 47404676)
35. Park TG,. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 1995; 15: 1123-1130.
36. Tracy MA, et al,. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999; 11: 1057-1062. (Pubitemid 29229474)
37. Sandor M, et al,. Effect of protein molecular weight on release from micron-sized PLGA microspheres. J Control Release 2001; 3: 297-311. (Pubitemid 32913438)
38. Siepmann J, et al,. Effect of the size of biodegradable microparticles on drug release: experiment and theory. J Control Release 2004; 1: 123-134. (Pubitemid 38438495)
39. Berchane NS, et al,. Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory. Int J Pharm 2007; 1-2: 118-126. (Pubitemid 46756043)
40. Faisant N, et al,. Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory. Int J Pharm 2006; 2: 189-197.
41. Larsen SW, et al,. On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds. Eur J Pharm Sci 2008; 1: 37-44.
42. Weng Larsen S, Larsen C,. Critical factors influencing the in vivo performance of long-acting lipophilic solutions-impact on in vitro release method design. AAPS J 2009; 4: 762-770.
43. Zuidema J, et al,. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 1994; 3: 189-207. (Pubitemid 24103997)
44. Fredholt K, et al,. Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur J Pharm Sci 2000; 3: 231-237. (Pubitemid 30616446)
45. Mantripragada S,. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res 2002; 5: 392-406. (Pubitemid 34712037)
46. Madan PL,. Sustained-release drug delivery systems: part V, parenteral products. Pharm Manuf 1985; 2: 51-57.
47. Larsen SW, et al,. In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur J Pharm Sci 2006; 5: 348-354. (Pubitemid 44709856)
48. Crommelin DJA, De Blaey CJ,. In vitro release studies on drugs suspended in non-polar media II. The release of paracetamol and chloramphenicol from suspensions in liquid paraffin. Int J Pharm 1980; 1: 29-42. (Pubitemid 11195086)
49. Larsen DH, et al,. Assessment of rate of drug release from oil vehicle using a rotating dialysis cell. Eur J Pharm Sci 2000; 3: 223-229. (Pubitemid 30616445)
50. Zentner GM, et al,. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 1-3: 203-215. (Pubitemid 32522358)
51. Packhaeuser CB, et al,. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004; 2: 445-455. (Pubitemid 39037247)
52. Chitkara D, et al,. Biodegradable injectable in situ depot-forming drug delivery systems. Macromol Biosci 2006; 12: 977-990. (Pubitemid 46032935)
53. Wang L, et al,. Drug release from injectable depots: two different in vitro mechanisms. J Control Release 2004; 2: 207-216. (Pubitemid 39222107)
54. McHugh AJ,. The role of polymer membrane formation in sustained release drug delivery systems. J Control Release 2005; 1-3: 211-221. (Pubitemid 41737265)
55. Hyun H, et al,. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier. Biomacromolecules 2007; 4: 1093-1100. (Pubitemid 46672685)
56. Kranz H, Bodmeier R,. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int J Pharm 2007; 1-2: 107-114. (Pubitemid 46227772)
57. Katakam M, et al,. Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J Control Release 1997; 1: 21-26. (Pubitemid 27417897)
58. Kempe S, et al,. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release 2008; 3: 220-225.
59. Kreye F, et al,. Lipid implants as drug delivery systems. Expert Opin Drug Deliv 2008; 3: 291-307. (Pubitemid 351454379)
60. Mohl S, Winter G,. Continuous release of rh-interferon [alpha]-2a from triglyceride matrices. J Control Release 2004; 1: 67-78. (Pubitemid 38624510)
61. Guse C, et al,. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. Int J Pharm 2006; 2: 137-144.
62. Koennings S, et al,. In vitro investigation of lipid implants as a controlled release system for interleukin-18. Int J Pharm 2006; 2: 145-152.
63. Herrmann S, et al,. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Release 2007; 2: 161-168. (Pubitemid 46343669)
64. Lim Soo P, et al,. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. Eur J Pharm Biopharm 2008; 1: 149-157.
65. Siepmann F, et al,. A novel mathematical model quantifying drug release from lipid implants. J Control Release 2008; 3: 233-240.
66. Gu F, et al,. Osmotic-driven release kinetics of bioactive therapeutic proteins from a biodegradable elastomer are linear, constant, similar, and adjustable. Pharm Res 2006; 4: 782-789.
67. Wright JC,. Critical variables associated with nonbiodegradable osmotically controlled implants. AAPS J 2010; 3: 437-442.
68. Iyer SS, et al,. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm Drug Dispos 2006; 4: 157-170. (Pubitemid 43797112)
69. Browne DC, Kieselmann K,. Low-level drug release-rate testing of ocular implants using USP Apparatus 4 dissolution and HPLC end analysis. Dissolution Technol 2010; 1: 12-14.
70. Shen J, Burgess DJ,. Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings. Int J Pharm 2012; 422: 341-348.
71. Makino K, et al,. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull (Tokyo) 1985; 3: 1195-1201. (Pubitemid 15104072)
72. Duda JL, Zielinski JM,. Free-volum theory. In:, Neogi P, ed. Diffusion in Polymers. Marcel Dekker. New York: The Marcel Dekker is the publisher, 1996: 309.
73. Kamberi M, et al,. A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: insight to the drug release mechanisms. Eur J Pharm Sci 2009; 3-4: 217-222.
74. Rawat A, et al,. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. Int J Pharm 2011; 2: 198-205.
75. D'Souza SS, et al,. A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres. AAPS PharmSciTech 2005; 4: E553-E564.
76. Zolnik BS, et al,. Elevated temperature accelerated release testing of PLGA microspheres. J Control Release 2006; 3: 293-300. (Pubitemid 43737147)
77. Makino K, et al,. Mechanism of hydrolytic degradation of poly(L-lactide) microcapsules: effects of pH, ionic strength and buffer concentration. J Microencapsul 1986; 3: 203-212. (Pubitemid 17195136)
78. de Jong SJ, et al,. New insights into the hydrolytic degradation of poly(lactic acid): participation of the alcohol terminus. Polymer 2001; 7: 2795-2802. (Pubitemid 32110031)
79. Koennings S, et al,. Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices. J Control Release 2007; 2: 173-181. (Pubitemid 46754503)
80. Walden M, et al,. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm 2007; 10: 1101-1111. (Pubitemid 350034834)
81. Zolnik BS, et al,. Application of USP Apparatus 4 and in situ fiber optic analysis to microsphere release testing. Dissolution Technol 2005; 12: 11-14.
82. Larsen SW, et al,. Assessment of drug release from oil depot formulations using an in vitro model-potential applicability in accelerated release testing. Drug Dev Ind Pharm 2008; 3: 297-304. (Pubitemid 351431198)
83. Murty SB, et al,. Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions. AAPS PharmSciTech 2003; 4: E50.
84. Voisine JM, et al,. In situ fiber optic method for long-term in vitro release testing of microspheres. Int J Pharm 2008; 1-2: 206-211.
85. Rawat A, Burgess DJ,. USP apparatus 4 method for in vitro release testing of protein loaded microspheres. Int J Pharm 2011; 1-2: 178-184.
86. Bhardwaj U, Burgess DJ,. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm 2010; 1-2: 287-294.
87. Schultz K, et al,. Rotating dialysis cell as in vitro release method for oily parenteral depot solutions. Int J Pharm 1997; 2: 163-169. (Pubitemid 27471168)
88. Saarinen-Savolainen P, et al,. Method for evaluating drug release from liposomes in sink conditions. Int J Pharm 1997; 1: 27-33. (Pubitemid 28062807)
89. Dash AK, et al,. Development of an in vitro dissolution method using microdialysis sampling technique for implantable drug delivery systems. J Pharm Sci 1999; 10: 1036-1040. (Pubitemid 29480596)
90. Pedersen BT, et al,. Characterization of the rotating dialysis cell as an in vitro model potentially useful for simulation of the pharmacokinetic fate of intra-articularly administered drugs. Eur J Pharm Sci 2005; 1: 73-79. (Pubitemid 40602197)
91. Costa P, Sousa Lobo JM,. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 2: 123-133. (Pubitemid 32288781)